For patients with invasive breast cancer who received epirubicin and cyclophosphamide followed by docetaxel (EC-T), the expressions of S100A6 and MDM2 were negatively correlated, and S100A6 was a predictive biomarker for the efficacy of neoadjuvant chemotherapy. Here, MDM2 is linked to invasive breast carcinoma.